Literature DB >> 27129778

Contribution of Accelerated Degradation to Feedback Regulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Cholesterol Metabolism in the Liver.

Seonghwan Hwang1, Isamu Z Hartman1, Leona N Calhoun1, Kristina Garland1, Gennipher A Young1, Matthew A Mitsche1, Jeffrey McDonald1, Fang Xu1, Luke Engelking1, Russell A DeBose-Boyd2.   

Abstract

Accumulation of sterols in endoplasmic reticulum membranes stimulates the ubiquitination of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), which catalyzes a rate-limiting step in synthesis of cholesterol. This ubiquitination marks HMGCR for proteasome-mediated degradation and constitutes one of several mechanisms for feedback control of cholesterol synthesis. Mechanisms for sterol-accelerated ubiquitination and degradation of HMGCR have been elucidated through the study of cultured mammalian cells. However, the extent to which these reactions modulate HMGCR and contribute to control of cholesterol metabolism in whole animals is unknown. Here, we examine transgenic mice expressing in the liver the membrane domain of HMGCR (HMGCR (TM1-8)), a region necessary and sufficient for sterol-accelerated degradation, and knock-in mice in which endogenous HMGCR harbors mutations that prevent sterol-induced ubiquitination. Characterization of transgenic mice revealed that HMGCR (TM1-8) is appropriately regulated in the liver of mice fed a high cholesterol diet or chow diet supplemented with the HMGCR inhibitor lovastatin. Ubiquitination-resistant HMGCR protein accumulates in the liver and other tissues disproportionately to its mRNA, indicating that sterol-accelerated degradation significantly contributes to feedback regulation of HMGCR in vivo Results of these studies demonstrate that HMGCR is subjected to sterol-accelerated degradation in the liver through mechanisms similar to those established in cultured cells. Moreover, these studies designate sterol-accelerated degradation of HMGCR as a potential therapeutic target for prevention of atherosclerosis and associated cardiovascular disease.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  cholesterol metabolism; endoplasmic reticulum (ER); endoplasmic-reticulum-associated protein degradation (ERAD); isoprenoid; lipid metabolism

Mesh:

Substances:

Year:  2016        PMID: 27129778      PMCID: PMC4919435          DOI: 10.1074/jbc.M116.728469

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

Review 1.  Protein sensors for membrane sterols.

Authors:  Joseph L Goldstein; Russell A DeBose-Boyd; Michael S Brown
Journal:  Cell       Date:  2006-01-13       Impact factor: 41.582

Review 2.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

3.  Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.

Authors:  E Reihnér; M Rudling; D Ståhlberg; L Berglund; S Ewerth; I Björkhem; K Einarsson; B Angelin
Journal:  N Engl J Med       Date:  1990-07-26       Impact factor: 91.245

4.  Turnover rate of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase as determined by use of cycloheximide.

Authors:  P A Edwards; R G Gould
Journal:  J Biol Chem       Date:  1972-03-10       Impact factor: 5.157

5.  Degradation of HMG-CoA reductase in rat liver is cholesterol and ubiquitin independent.

Authors:  Gene C Ness; Reed C Holland
Journal:  FEBS Lett       Date:  2005-06-06       Impact factor: 4.124

6.  A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice.

Authors:  W S Simonet; N Bucay; S J Lauer; J M Taylor
Journal:  J Biol Chem       Date:  1993-04-15       Impact factor: 5.157

7.  Schoenheimer effect explained--feedback regulation of cholesterol synthesis in mice mediated by Insig proteins.

Authors:  Luke J Engelking; Guosheng Liang; Robert E Hammer; Kiyosumi Takaishi; Hiroshi Kuriyama; Bret M Evers; Wei-Ping Li; Jay D Horton; Joseph L Goldstein; Michael S Brown
Journal:  J Clin Invest       Date:  2005-08-11       Impact factor: 14.808

8.  Insig-dependent ubiquitination and degradation of mammalian 3-hydroxy-3-methylglutaryl-CoA reductase stimulated by sterols and geranylgeraniol.

Authors:  Navdar Sever; Bao-Liang Song; Daisuke Yabe; Joseph L Goldstein; Michael S Brown; Russell A DeBose-Boyd
Journal:  J Biol Chem       Date:  2003-10-16       Impact factor: 5.157

9.  Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a.

Authors:  H Shimano; J D Horton; R E Hammer; I Shimomura; M S Brown; J L Goldstein
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

Review 10.  Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR).

Authors:  Laura J Sharpe; Andrew J Brown
Journal:  J Biol Chem       Date:  2013-05-21       Impact factor: 5.157

View more
  16 in total

Review 1.  Post-translational control of the long and winding road to cholesterol.

Authors:  Laura J Sharpe; Hudson W Coates; Andrew J Brown
Journal:  J Biol Chem       Date:  2020-12-18       Impact factor: 5.157

2.  "Mallostery"-ligand-dependent protein misfolding enables physiological regulation by ERAD.

Authors:  Margaret A Wangeline; Randolph Y Hampton
Journal:  J Biol Chem       Date:  2018-07-17       Impact factor: 5.157

Review 3.  Post-translational control of the long and winding road to cholesterol.

Authors:  Laura J Sharpe; Hudson W Coates; Andrew J Brown
Journal:  J Biol Chem       Date:  2020-10-13       Impact factor: 5.157

4.  Hypoxia-inducible factor 1α activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver.

Authors:  Seonghwan Hwang; Andrew D Nguyen; Youngah Jo; Luke J Engelking; James Brugarolas; Russell A DeBose-Boyd
Journal:  J Biol Chem       Date:  2017-04-17       Impact factor: 5.157

5.  UbiA prenyltransferase domain-containing protein-1 modulates HMG-CoA reductase degradation to coordinate synthesis of sterol and nonsterol isoprenoids.

Authors:  Marc M Schumacher; Dong-Jae Jun; Brittany M Johnson; Russell A DeBose-Boyd
Journal:  J Biol Chem       Date:  2017-11-22       Impact factor: 5.157

6.  Schnyder corneal dystrophy-associated UBIAD1 is defective in MK-4 synthesis and resists autophagy-mediated degradation.

Authors:  Dong-Jae Jun; Marc M Schumacher; Seonghwan Hwang; Lisa N Kinch; Nick V Grishin; Russell A DeBose-Boyd
Journal:  J Lipid Res       Date:  2020-03-18       Impact factor: 5.922

Review 7.  Proteostatic Tactics in the Strategy of Sterol Regulation.

Authors:  Margaret A Wangeline; Nidhi Vashistha; Randolph Y Hampton
Journal:  Annu Rev Cell Dev Biol       Date:  2017-10-06       Impact factor: 13.827

8.  Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol.

Authors:  Shi-You Jiang; Hui Li; Jing-Jie Tang; Jie Wang; Jie Luo; Bing Liu; Jin-Kai Wang; Xiong-Jie Shi; Hai-Wei Cui; Jie Tang; Fan Yang; Wei Qi; Wen-Wei Qiu; Bao-Liang Song
Journal:  Nat Commun       Date:  2018-12-03       Impact factor: 14.919

9.  Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1.

Authors:  Manisha Juneja; Dennis Kobelt; Wolfgang Walther; Cynthia Voss; Janice Smith; Edgar Specker; Martin Neuenschwander; Björn-Oliver Gohlke; Mathias Dahlmann; Silke Radetzki; Robert Preissner; Jens Peter von Kries; Peter Michael Schlag; Ulrike Stein
Journal:  PLoS Biol       Date:  2017-06-01       Impact factor: 8.029

10.  Concomitant attenuation of HMG-CoA reductase expression potentiates the cancer cell growth-inhibitory effect of statins and expands their efficacy in tumor cells with epithelial characteristics.

Authors:  Takuro Ishikawa; Yoshinao Z Hosaka; Colin Beckwitt; Alan Wells; Zoltán N Oltvai; Katsuhiko Warita
Journal:  Oncotarget       Date:  2018-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.